BioSpace News Archive

CytoSorbents Corporation issues a stockholder letter from its Chief Executive Officer, Dr. Phillip Chan, and announces preliminary unaudited fourth quarter 2022 and full year 2022 results ahead of filing its Form 10-K.

Reneo Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted mavodelpar Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD).

KemPharm, Inc. announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs.

Medicenna Therapeutics Corp. today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023.

Microbot Medical Inc. (Nasdaq: MBOT) announced the next episode of its highly successful “Access-Ability Live by MBOT” webinar, which is intended for all stakeholders interested in the endovascular robotic space and will be held on Wednesday, February 8, 2023, at 1:00pm ET. It will be hosted by the Company’s Chief Medical Officer, Dr. Eyal Morag.

Coeptis Therapeutics Holdings, Inc. today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology.

Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital.

Aptinyx Inc. today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.

EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced positive clinical results from the Endo-HIFU-R1 Phase 2 study evaluating the safety of therapeutic high-Intensity focused ultrasound (HIFU) for the treatment of rectal endometriosis.

Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, will release its fourth quarter and full-year 2022 financial results on Tuesday, Feb. 28, after market close.